Protective immunisation of mice using cell surface glycoprotein from Trypanosoma cruzi
Protective immunisation of mice using cell surface glycoprotein from Trypanosoma cruzi
复制标题
使用克氏锥虫细胞表面糖蛋白对小鼠进行保护性免疫
作者：
M. Scott;D. Snary
寄生原生动物克氏锥虫（Trypanosoma cruzi）是人类慢性衰弱性恰加斯病的病原体。cruzi，迄今为止还没有合适的化学疗法1，2。由于原生动物中存在内毒素样物质3以及T.与哺乳动物心脏和神经组织交叉反应，从而刺激针对哺乳动物心脏和神经组织的免疫4，5。由于以这种方式诱导的自身免疫被认为会导致疾病慢性阶段的心脏和神经病变特征6，7，因此假设基于全生物体疫苗的免疫接种可能具有自身诱导疾病症状的风险。最近从T.克鲁兹它是唯一的主要细胞表面糖蛋白，存在于寄生虫的整个生命周期8，并且不经历抗原变异9。我们已经成功地保护小鼠免受急性致死性T。通过用糖蛋白与佐剂的组合接种它们来预防克氏感染。此外，这种糖蛋白似乎不是携带引起自身免疫抗体形成的抗原的糖蛋白。
The parasitic protozoan Trypanosoma cruzi is the causative agent of the chronic debilitating Chagas' disease in man. It is estimated that at least 12 million people in South and Central America are infected with T. cruzi, for which there is so far no suitable chemotherapy1,2. The development of vaccines using killed or attenuated whole organisms is hindered by the presence of endotoxin-like material in the protozoa3, and the possible existence of antigens in T. cruzi which cross-react with, and thereby stimulate immunity against, mammalian heart and nervous tissue4,5. Because autoimmunity induced in this way has been thought to cause the cardiac and neural lesions characteristic of the chronic stage of the disease6,7, it has been assumed that immunisation based on a whole organism vaccine might carry the risk of itself inducing symptoms of the disease. Recently an integral membrane glycoprotein of molecular weight 90,000, was isolated from the cell surface of T. cruzi. It is the only major cell surface glycoprotein, it is present throughout the life cycle of the parasite8, and it does not undergo antigenic variation9. We have successfully protected mice against acute lethal T. cruzi infection by vaccinating them with glycoprotein in combination with adjuvants. Moreover this glycoprotein does not seem to be the one carrying the antigens causing autoimmune antibody formation.